Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13663382 | 0.82 | ALDH1A1 (0.51) | HRH3ALDH1A1CYP2D6MAPTACKR3 | |
| SCHEMBL24733368 | 0.79 | HRH3 (0.47) | EPHX1HRH3ALDH1A1CYP2D6MAPT | |
| SCHEMBL12162963 | 0.79 | EPHX1 (0.80) | EPHX1ALDH1A1MAPT | |
| SCHEMBL12163057 | 0.79 | EPHX1 (0.88) | EPHX1ALDH1A1MAPT | |
| SCHEMBL20147696 | 0.79 | HRH3 (0.42) | EPHX1HRH3 | |
| SCHEMBL15131702 | 0.79 | HSD11B1 (0.49) | HRH3ALDH1A1CYP2D6MAPTACKR3 | |
| SCHEMBL18855728 | 0.77 | EPHX1 (0.92) | EPHX1ALDH1A1MAPT | |
| SCHEMBL1456569 | 0.76 | CTSK (0.55) | EPHX1HRH3ALDH1A1CYP2D6MAPT | |
| SCHEMBL222409 | 0.76 | ALDH1A1 (0.47) | HRH3ALDH1A1CYP2D6MAPTACKR3 | |
| SCHEMBL20365873 | 0.76 | EPHX1 (0.96) | EPHX1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | EPHX1 1481/4885HRH3 1000/4885ALDH1A1 2547/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | EPHX1 1481/4885HRH3 1000/4885ALDH1A1 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.